Essent Biologics
Supplies human-derived biomaterials like micronized bone matrix as bioink additives for 3D bioprinting and tissue engineering, enabling animal-free drug testing and regenerative medicine research.
- CEO / Founder
- Corey Stone
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- Undisclosed
- Key Investors
- AlloSource
Technology & Products
Key Products
Human-derived biomaterials, micronized bone matrix, human adipose-derived MSCs, and scaffold materials for 3D bioprinting and tissue engineering.
Technological Advantage
Proprietary access to human tissue donations via AlloSource, enabling high-quality, biologically relevant materials with GMP compliance; advantage is defensible through sourcing relationships and regulatory expertise.
Differentiation
Value Proposition
Provides biologically relevant, human-derived scaffold materials (e.g., micronized bone matrix) that reduce reliance on animal models, accelerate research from benchtop to bedside, and support advanced 3D bioprinting applications with GMP-compliant quality.
How They Differentiate
Focuses exclusively on human-derived biomaterials for 3D bioprinting, unlike competitors that may use animal sources or broader regenerative implants; offers custom biomanufacturing and comprehensive donor data.
Market & Competition
Target Customers
Researchers in regenerative medicine, biopharmaceuticals, cell therapy, and tissue engineering
Industry Verticals
Biotechnology; Regenerative Medicine; Pharmaceuticals; Medical Research; Tissue Engineering
Competitors
Organogenesis Holdings Inc.; Acelity L.P. Inc.; Integra LifeSciences; Ossium Health; Xtant Medical
Growth & Milestones
Growth Metrics
Launched after two years of stealth-mode operation; supplies products in small or large volumes; serves as a manufacturing partner creating master cell banks and custom product inventory
Major Milestones
Launched publicly in January 2021 after two years in stealth mode; Released Micronized Bone Matrix for 3D bioprinting in 2022; Partnered with Amnion Foundation in December 2021 for germinal-origin stem cells
Notable Customers
Academic research groups and biopharmaceutical companies (e.g., Validus Cellular Therapeutics).